A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with dose limiting toxicities (DLTs)

DLTs will be evaluated during the first cycle (21 days) as a single agent (phase 1a monotherapy) or in combination with other agents (phase 1b dose escalation)

Time frame: Cycle 1 (21 days)

Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with treatment-emergent adverse events (AEs)

AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy

Time frame: Baseline to 28 days after last dose of study medication

Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in laboratory abnormalities

Laboratory abnormalities as characterized by type, frequency, severity, and timing.

Time frame: Baseline to 28 days after last dose of study treatment

Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in vital sign abnormalities

Vital sign abnormalities as characterized by type, frequency, severity, and timing.

Time frame: Baseline to 28 days after last dose of study treatment

Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in physical exam abnormalities

Physical exam abnormalities as as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Time frame: Baseline to 28 days after last dose of study treatment

Phase 1b Dose Expansion: Overall response rate (ORR)

Response will be evaluated via radiographical tumor assessments by RECIST v1.1 for solid tumors or RANO for primary brain tumors

Time frame: Baseline to 2 years